Hepatitis B vaccine recombinant - Merck
Alternative Names: HBvaxPRO; Hepatitis B vaccine (rDNA) - MerckLatest Information Update: 02 Jan 2023
At a glance
- Originator sanofi pasteur MSD
- Developer Merck & Co; sanofi pasteur MSD
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 02 Jan 2023 Phase III developemnt in Hepatitis B (Prevention) is still ongoing in Finland (IM)
- 29 Dec 2020 Merck Sharp & Dohme completes a phase III trial in Hepatitis B (Prevention) in Finland (IM, Injection) (NCT04490499)
- 05 Sep 2020 Phase-III clinical trials in Hepatitis B (Prevention) in Finland (IM) (NCT04490499)